<?xml version="1.0" encoding="UTF-8"?>
<p>This review covers the information available today. As the COVID-19 pandemic progresses, there is an opportunity and responsibility to collect prospective data using established randomised controlled trial involving drugs of interest and cohort-based translational studies. 
 <list list-type="order">
  <list-item>
   <p>All cytotoxic chemotherapy</p>
  </list-item>
  <list-item>
   <p>Low-dose steroids and non-steroidal anti-inflammatory drugs (NSAIDs)</p>
  </list-item>
  <list-item>
   <p>Any tumour necrosis factor (TNF) blocker</p>
  </list-item>
  <list-item>
   <p>interlukin-6 (IL-6) blockade</p>
  </list-item>
  <list-item>
   <p>Janus kinase (JAK) inhibitors</p>
  </list-item>
  <list-item>
   <p>IL-1 blockade</p>
  </list-item>
  <list-item>
   <p>Mycophenolate</p>
  </list-item>
  <list-item>
   <p>Tacrolimus</p>
  </list-item>
  <list-item>
   <p>Anti-CD20</p>
  </list-item>
  <list-item>
   <p>CTLA4-Ig</p>
  </list-item>
 </list>
</p>
